AJANTPHARM / Q2-FY25 / claim-ledger

Audit the questions that mattered.

Ajanta Pharma · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ2-FY25 · 2024-11-12Back to quarter ↗

Questions audited

Answered directly

86%

Numeric claims

Consistency

mixed

Question ledger

What was answered, and how?

Sudarshan Padmanabhan · JM Financial PMS

partial

Asked about other costs increase excluding FX and SG&A sustainability.

So if you take a full half year, you know, that is something which is the most reasonable amount which you should consider for the expenses side. Because as against INR 534 crores last year, we have spent about INR 616 crores.

Sudarshan Padmanabhan · JM Financial PMS

direct

Asked about volume growth and MR expansion strategy.

We are growing at one point five times the industry volume growth. ... I think we should be able to continue to perform better than the IPM in the volume growth, even in the coming few quarters.

Foram Parekh · BOB Capital

direct

Asked about sustainability of 16% India business growth.

Absolutely. Absolutely. That's correct. ... overall, we should expect 9%-10% kind of run rate going forward.

Foram Parekh · BOB Capital

direct

Asked about growth drivers in Asia region.

It's increase in the market share on the existing products, and there have been new product launches which we have done. And also we've added the people.

Ankush Mahajan · Axis Securities

partial

Asked about US business strategy and expected run rate.

U.S., for the current year, will be a single digit type of growth. ... we will be looking to launch around four products. ... next year onwards, hopefully, we have more approvals.

Abdulkader Puranwala · ICICI Securities

direct

Asked about second half revenue growth and branded generic guidance.

We feel that we are on course to deliver that kind of numbers for the branded generic business. ... for the whole year, I think we feel comfortable in giving the guidance of the mid-teen.

Kunal Randeria · Axis Capital

declined

Asked about Asia business breakdown by country.

Sir, we don't give you a breakup of the Asia. It's a combination of that. It doesn't really matter.

Kunal Randeria · Axis Capital

direct

Asked about dividend implying no inorganic activity.

Inorganic activity, as of now, well, clearly, we don't have anything, so, but we can't rule it out for the future.

Tushar Manudhane · Motilal Oswal Financial Services

partial

Asked about gross margin improvement and sustainability.

It depends on the product mix, actually. ... variation can be there of 50-100 basis points, depending on the, you know, product mix which is there.

Tushar Manudhane · Motilal Oswal Financial Services

direct

Asked about EBITDA margin guidance for FY25.

EBITDA margin guidance for the whole year from the beginning we said 28%, plus or minus 1% can be there. ... we're still holding true to that.

Rashmi Sancheti · Dolat Capital

direct

Asked about Africa business QoQ decline and second half outlook.

In the Q4 of the last year, our sales were slightly on the lower side ... some of the sales got pushed out into the Q1 of this year. ... For the next quarters, run rate will be slightly lower than this.

Vishal Manchanda · Systematix

direct

Asked about India cardiac and pain segment growth vs market.

For Q2, we have substantially outpaced the covered market growth in the cardiology. We are at 16%, whereas versus the covered market is at 8%.